Everolimus First-line Therapy in Non-rapidly Progressive Castration Resistant Prostate Cancer (CRPC). A Multicenter Phase II Trial.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 14 Feb 2018
At a glance
- Drugs Everolimus (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 09 Feb 2018 Planned End Date changed from 31 Dec 2017 to 31 Dec 2031.
- 10 Jun 2017 Biomarkers information updated
- 20 Jun 2012 Actual patient number is 37 according to ClinicalTrials.gov.